The present report summarises some of the data shared during the last European Bone Marrow Transplant (EBMT) meeting that was held virtually from the 29th of August to the 1st of September 2020. It is certainly not exhaustive but reflects the author’s selection of relevant data for clinical practice as well as future developments in the field. Cellular therapy against multiple myeloma and non-Hodgkin’s lymphoma were extensively covered in other recent congresses and were not included in this report.

(BELG J HEMATOL 2020;11(7):335-8)